Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator

Endocrinology

Volumn 150, Issue 9, 2009, Pages 4012-4023

  David, Valentin ^a   Martin, Aline ^a   Hedge, Anne Marie ^a   Rowe, Peter S N ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Kidney Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; GENE CONTROL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; KIDNEY CALCIFICATION; KIDNEY TUBULE ABSORPTION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINALYSIS; VASCULARIZATION;

AGING; ALDOSTERONE; ANIMAL NUTRITIONAL PHYSIOLOGICAL PHENOMENA; ANIMALS; BONE AND BONES; BONE DEVELOPMENT; CALCITRIOL; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; PARATHYROID HORMONE; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHOPROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 69249117464     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0216     Document Type: Article

References (51)

1. Strom TM, Jüppner H 2008 PHEX, FGF23, DMP1 and beyond. Curr Opin Nephrol Hypertens 17:357-362
2. Kiela PR, Ghishan FK 2008 Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest 24:24
3. Qin C, D'Souza R, Feng JQ 2007 Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis. J Dent Res 86:1134-1141
4. Rowe PSN 2004 The wrickkened-pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15:264-281
5. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL 2000 MEPE, a new gene expressed in bone-marrow and tumours causing osteomalacia. Genomics 67:54-68
6. Addison WN, Nakano Y, Loisel T, Crine P, McKee MD 2008 MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite-an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23:1638-1649
7. Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS 2008 Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757-1772
8. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA 2003 Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998-2007
9. Hayashibara T, Hiraga T, Sugita A, Wang L, Hata K, Ooshima T, Yoneda T 2007 Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res 22:1743-1751
10. Dobbie H, Unwin RJ, Faria NJ, Shirley DG 2008 Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 23:730-733
11. Marks J, Churchill LJ, Debnam ES, Unwin RJ 2008 Matrix extracellular phosphoglycoprotein inhibits intestinal phosphate transport. J Am Soc Nephrol 19:2313-2320
12. Rowe PSN, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR 2004 MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-319
13. Rowe PS, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE 2005 Surface plasmon resonance (SPR) confirms MEPE binds to PHEX via the MEPE-ASARM-motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36:33-46
14. Zhao M, Harris SE, Horn D, Geng Z, Nishimura R, Mundy GR, Chen D 2002 Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol 157:1049-1060
15. David V, Lafage-Proust MH, Laroche N, Christian A, Ruegsegger P, Vico L 2006 Two-week longitudinal survey of bone architecture alteration in the hindlimb-unloaded rat model of bone loss: sex differences. Am J Physiol Endocrinol Metab 290:E440-E447
16. Barou O, Valentin D, Vico L, Tirode C, Barbier A, Alexandre C, Lafage-Proust MH 2002 High-resolution three-dimensional microcomputed tomography detects bone loss and changes in trabecular architecture early: comparison with DEXA and bone histomorphometry in a rat model of disuse osteoporosis. Invest Radiol 37:40-46
17. Martin A, David V, Vico L, Thomas T 2008 Impaired energetic metabolism after central leptin signaling leads to massive appendicular bone loss in hindlimb-suspended rats. J Bone Miner Res 23:2040-2047
18. Solari F, Flamant F, Cherel Y, Wyers M, Jurdic P 1996 The osteoclast generation: an in vitro and in vivo study with a genetically labelled avian monocytic cell line. J Cell Sci 109(Pt 6):1203-1213
19. Rowe PS, Matsumoto N, Jo OD, Shih RN, Oconnor J, Roudier MP, Bain S, Liu S, Harrison J, Yanagawa N 2006 Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 39:773-786
20. Dacquin R, Starbuck M, Schinke T, Karsenty G 2002 Mouse α1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev Dyn 224:245-251
21. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Jüppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094
22. Ogbureke KU, Fisher LW 2005 Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int 68:155-166
23. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, Crine P, Juliano L, Boileau G, Carmona AK 2003 Human recombinant endopeptidase PHEX has a strict S1′ specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 373:271-279
24. Bresler D, Bruder J, Mohnike KL, Fraser WD, Rowe PS 2004 Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 183:R1-R9
25. Hoffman WH, Jain A, Chen H, Fedarko NS 2008 Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome. Am J Med Genet A 146A:2164-2168
26. Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M, Fisher LW 2004 Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 89:4158-4161
27. Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK 2008 Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118:722-734
28. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G 2007 Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469
29. De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC 2002 Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102-1110
30. Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy Jr WA, Gagel RF, Hoff AO 2008 Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 14:1108-1114
31. Seufert J, Ebert K, Müller J, Eulert J, Hendrich C, Werner E, Schuüze N, Schulz G, Kenn W, Richtmann H, Palitzsch KD, Jakob F 2001 Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345:1883-1888
32. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
33. Woznowski M, Quack I, Stegbauer J, Büchner N, Rump LC, Schieren G 2008 Oncogenic osteomalacia, a rare paraneoplastic syndrome due to phosphate wasting - a case report and review of the literature. Clin Nephrol 70:431-438
34. Nampei A, Hashimoto J, Hayashida K, Tsuboi H, Shi K, Tsuji I, Miyashita H, Yamada T, Matsukawa N, Matsumoto M, Morimoto S, Ogihara T, Ochi T, Yoshikawa H 2004 Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 22:176-184
35. Harris SE, Gluhak-Heinrich J, Harris MA, Yang W, Bonewald LF, Riha D, Rowe PS, Robling AG, Turner CH, Feng JQ, McKee MD, Nicollela D 2007 DMP1 and MEPE expression are elevated in osteocytes after mechanical loading in vivo: theoretical role in controlling mineral quality in the perilacunar matrix. J Musculoskelet Neuronal Interact 7:313-315
36. Ogbureke KU, Fisher LW 2004 Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res 83:664-670
37. Yang W, Harris SE, Raw P, Feng J, Gluhak-Heinrich J 2006 MEPE over-expression in osteocytes of Dmp1 null mice by activation of the PKA/CREB pathway. J Bone Miner Res 21:S136-S136
38. Argiro L, Desbarats M, Glorieux FH, Ecarot B 2001 Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 74:342-351
39. Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD 2007 Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 192:261-267
40. Dubois SG, Ruchon AF, Delalandre A, Boileau G, Lajeunesse D 2002 Role of abnormal neutral endopeptidase-like activities in Hyp mouse bone cells in renal phosphate transport. Am J Physiol Cell Physiol 283:C1414-C1421
41. Matsumoto N, Jo OD, Shih RN, Brochmann EJ, Murray SS, Hong V, Yanagawa J, Yanagawa N 2005 Increased cathepsin D release by Hyp mouse osteoblast cells. Am J Physiol Endocrinol Metab 289:E123-E132
42. Matsumoto N, Jo OD, Shih RN, Yanagawa N 2005 Altered cathepsin D metabolism in PHEX antisense human osteoblast cells. Biochem Biophys Res Commun 332:248-253
43. Martin A, David V, Hedge A, Rowe PSN 2008 MEPE C-terminal ASARM-peptide promotes hypophosphatemia, bone defects and increases adiposity. J Bone Miner Res 23:S103
44. Chau H, El-Maadawy S, McKee MD, Tenenhouse HS 2003 Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2. J Bone Miner Res 18:644-657
45. Verhulst A, Asselman M, De Naeyer S, Vervaet BA, Mengel M, Gwinner W, D'Haese PC, Verkoelen CF, De Broe ME 2005 Preconditioning of the distal tubular epithelium of the human kidney precedes nephrocalcinosis. Kidney Int 68:1643-1647
46. Takayama S, Ishii S, Ikeda T, Masamura S, Doi M, Kitajima M 2005 The relationship between bone metastasis from human breast cancer and integrin α(v)β3 expression. Anticancer Res 25:79-83
47. Schiffrin EL 2006 Effects of aldosterone on the vasculature. Hypertension 47:312-318
48. Michel F, Ambroisine ML, Duriez M, Delcayre C, Levy BI, Silvestre JS 2004 Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation 109:1933-1937
49. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J 2007 Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13:189-197
50. Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, Nimura Y, Ishida J, Fukamizu A, Ikeda K 2008 Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 10:10
51. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R 2008 Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 22:2465-2475